Description
EMPA M 12.5/500mg is a powerful combination tablet specifically designed for the comprehensive management of type 2 diabetes. It contains Empagliflozin (12.5mg), an SGLT2 inhibitor that helps the kidneys remove excess glucose from the body through urine, and Metformin (500mg), a biguanide that reduces glucose production by the liver and improves the body’s sensitivity to insulin. This dual-action approach effectively lowers blood sugar levels. Beyond glycemic control, EMPA M 12.5/500mg also offers significant benefits in reducing the risk of cardiovascular death, heart failure hospitalization, and the progression of chronic kidney disease in adults with type 2 diabetes. Used alongside diet and exercise, it provides a robust solution for holistic diabetes care
